254 related articles for article (PubMed ID: 18359089)
1. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response.
Djoba Siawaya JF; Bapela NB; Ronacher K; Veenstra H; Kidd M; Gie R; Beyers N; van Helden P; Walzl G
J Infect; 2008 May; 56(5):340-7. PubMed ID: 18359089
[TBL] [Abstract][Full Text] [Related]
2. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.
Brahmbhatt S; Black GF; Carroll NM; Beyers N; Salker F; Kidd M; Lukey PT; Duncan K; van Helden P; Walzl G
Clin Exp Immunol; 2006 Nov; 146(2):243-52. PubMed ID: 17034576
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Ostrowski SR; Ravn P; Hoyer-Hansen G; Ullum H; Andersen AB
Scand J Infect Dis; 2006; 38(11-12):1028-32. PubMed ID: 17148072
[TBL] [Abstract][Full Text] [Related]
4. Resolution of the acute-phase response in West African patients receiving treatment for pulmonary tuberculosis.
Lawn SD; Obeng J; Acheampong JW; Griffin GE
Int J Tuberc Lung Dis; 2000 Apr; 4(4):340-4. PubMed ID: 10777083
[TBL] [Abstract][Full Text] [Related]
5. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis.
Giosuè S; Casarini M; Ameglio F; Zangrilli P; Palla M; Altieri AM; Bisetti A
Eur Cytokine Netw; 2000 Mar; 11(1):99-104. PubMed ID: 10705306
[TBL] [Abstract][Full Text] [Related]
6. Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy.
Baumann R; Kaempfer S; Chegou NN; Nene NF; Veenstra H; Spallek R; Bolliger CT; Lukey PT; van Helden PD; Singh M; Walzl G
Tuberculosis (Edinb); 2013 Mar; 93(2):239-45. PubMed ID: 23127778
[TBL] [Abstract][Full Text] [Related]
7. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea.
Azzurri A; Kanaujia GV; Sow OY; Bah B; Diallo A; Del Prete G; Gennaro ML
Int J Immunopathol Pharmacol; 2006; 19(1):199-208. PubMed ID: 16569358
[TBL] [Abstract][Full Text] [Related]
8. alpha1-acid glycoprotein and alpha1-antitrypsin as early markers of treatment response in patients receiving the intensive phase of tuberculosis therapy.
Almeida ML; Barbieri MA; Gurgel RQ; Abdurrahman ST; Baba UA; Hart CA; Shenkin A; Silva AM; de Souza L; Cuevas LE
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):575-80. PubMed ID: 19211120
[TBL] [Abstract][Full Text] [Related]
9. Prediction of delayed treatment response in pulmonary tuberculosis: use of time to positivity values of Bactec cultures.
Carroll NM; Uys P; Hesseling A; Lawrence K; Pheiffer C; Salker F; Duncan K; Beyers N; van Helden PD
Tuberculosis (Edinb); 2008 Nov; 88(6):624-30. PubMed ID: 18456556
[TBL] [Abstract][Full Text] [Related]
10. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
11. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
Eugen-Olsen J; Gustafson P; Sidenius N; Fischer TK; Parner J; Aaby P; Gomes VF; Lisse I
Int J Tuberc Lung Dis; 2002 Aug; 6(8):686-92. PubMed ID: 12150480
[TBL] [Abstract][Full Text] [Related]
12. [A study on the implementation of primary chemotherapy to pulmonary tuberculosis with positive bacillus].
Tian XZ; Wang LX
Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Aug; 16(4):220-2. PubMed ID: 7585902
[TBL] [Abstract][Full Text] [Related]
13. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
14. [Problems in the treatment of patients with pulmonary tuberculosis].
Chukanov VI
Probl Tuberk; 1997; (4):17-9. PubMed ID: 9333807
[TBL] [Abstract][Full Text] [Related]
15. The early bactericidal activity of anti-tuberculosis drugs: a literature review.
Donald PR; Diacon AH
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S75-83. PubMed ID: 18762155
[TBL] [Abstract][Full Text] [Related]
16. sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis.
Demir T; Yalçinoz C; Keskinel I; Demiröz F; Yildirim N
Int J Tuberc Lung Dis; 2002 Feb; 6(2):155-9. PubMed ID: 11931415
[TBL] [Abstract][Full Text] [Related]
17. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
18. Treatment end point determinants for pulmonary tuberculosis: human resistin as a surrogate biomarker.
Ehtesham NZ; Nasiruddin M; Alvi A; Kumar BK; Ahmed N; Peri S; Murthy KJ; Hasnain SE
Tuberculosis (Edinb); 2011 Jul; 91(4):293-9. PubMed ID: 21606003
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of smear negative pulmonary tuberculosis among patients visiting St. Peter's Tuberculosis Specialized Hospital, Addis Ababa, Ethiopia.
Desta K; Asrat D; Lemma E; Gebeyehu M; Feleke B
Ethiop Med J; 2009 Jan; 47(1):17-24. PubMed ID: 19743776
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of cytomorphology of tuberculous lymphadenitis and changes during anti-tubercular treatment.
Sharma M; Agarwal S; Wadhwa N; Mishra K; Gadre DJ
Cytopathology; 2007 Jun; 18(3):180-3. PubMed ID: 17388932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
